(Q50742818)

18 March 2018

title

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. (English)

1 reference

18 March 2018

0 references

1 reference

3

1 reference

18 March 2018

author name string

Jean-Luc Canon

1

1 reference

18 March 2018

Johan Vansteenkiste

2

1 reference

18 March 2018

M Victoria Mateos

4

1 reference

18 March 2018

Laurent Bastit

5

1 reference

18 March 2018

Irene Ferreira

6

1 reference

18 March 2018

Greg Rossi

7

1 reference

18 March 2018

Rafael G Amado

8

1 reference

18 March 2018

language of work or name

English

0 references

publication date

1 February 2006

1 reference

18 March 2018

Journal of the National Cancer Institute

published in

1 reference

18 March 2018

volume

98

1 reference

18 March 2018

issue

4

1 reference

18 March 2018

page(s)

273-284

1 reference

18 March 2018

Chemotherapy-induced anemia in adults: incidence and treatment

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

New erythropoietic proteins: rationale and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ053

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJJ053

1 reference

18 March 2018

PubMed ID

16478746

1 reference

18 March 2018